Login / Signup

Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis.

Andrew BlauveltKenneth B GordonPatricia LeeJerry BagelHoward SofenBenjamin LockshinAhmed M SolimanZiqian GengTianyu ZhanGabriela AlperovichLinda F Stein Gold
Published in: The Journal of dermatological treatment (2021)
NCT03875482 and NCT0387508.
Keyphrases
  • drug delivery
  • coronary artery disease
  • high intensity
  • electronic health record
  • early onset
  • health information
  • healthcare
  • atopic dermatitis
  • drug induced